Male sex was associated with a 10% lower risk of discontinuing antihypertensive drug treatment compared with female sex (RR 0.90; 95% CI 0.88-0.92).
Cohort (n=60,526)
Does male sex reduce the risk of antihypertensive treatment discontinuation compared to female sex in newly treated patients?
In a real-world setting, men demonstrate higher persistence to newly initiated antihypertensive drug therapy than women.
Relative Risk: 0.9 (95% CI 0.88–0.92)
OBJECTIVE: Several factors affect adherence to antihypertensive drug treatment, but whether these factors include a sex difference is unclear. Aim of the study was to compare persistence with antihypertensive drug therapy between men and women in a large cohort of patients. METHODS: The 60 526 residents of the Italian Lombardy Region aged 40-80 years newly treated with antihypertensive drugs during 2010 were identified and followed for 1 year after the first prescription. Discontinuation of treatment was defined as lack of prescription renewal for at least 90 days. Log-binomial regression models were fitted to estimate the risk ratio of treatment discontinuation in relation to sex. Other than for the whole population, analyses were stratified according to age, comorbidity status and the initial antihypertensive treatment strategy. RESULTS: Thirty-seven percent of the patients discontinued the drug treatment during follow-up. Compared with women, men had a 10% lower risk of discontinuation of drug treatment (95% confidence interval: 8-12). Persistence on antihypertensive treatment was better in men than in women, this being the case in both younger (40-64 years) and older patients (65-80 years), in patients starting treatment with any major antihypertensive drug and in patients who had a low comorbidity status. There was no evidence that men and women had a different risk of treatment discontinuation when their comorbidity status was worse, or initial antihypertensive treatment was based on drug combinations. CONCLUSION: Our data show that in a real-life setting, men are more persistent to antihypertensive drug therapy than women.
Rea et al. (Thu,) conducted a cohort in Hypertension (newly treated) (n=60,526). Male sex vs. Female sex was evaluated on Discontinuation of treatment (lack of prescription renewal for at least 90 days) (RR 0.90, 95% CI 0.88-0.92). Male sex was associated with a 10% lower risk of discontinuing antihypertensive drug treatment compared with female sex (RR 0.90; 95% CI 0.88-0.92).